BioMarin Pharmaceutical(DE:BM8)
€50.92+0.28 (+2.50%)
DE:BM8
BioMarin Pharmaceutical financials statements
€50.92
At close:+0.28 (+2.50%)
BioMarin Pharmaceutical (BM8) Ratios
1 Followers
BioMarin Pharmaceutical Ratios
DE:BM8's free cash flow for Q3 2026 was $159.92M. For the 2026 fiscal year, DE:BM8's free cash flow was decreased by $-28.29M and operating cash flow was $188.21M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 5.21 | 5.33 | 2.51 | 4.67 | 4.16 |
| Quick Ratio | 3.50 | 3.29 | 1.57 | 3.15 | 2.74 |
| Cash Ratio | 1.73 | 1.55 | 0.64 | 1.23 | 1.07 |
| Solvency Ratio | 0.28 | 0.39 | 0.14 | 0.14 | 0.03 |
| Operating Cash Flow Ratio | 1.09 | 0.94 | 0.14 | 0.30 | 0.56 |
| Short-Term Operating Cash Flow Coverage | 95.34 | 24.83 | 0.32 | 0.00 | 0.00 |
| Net Current Asset Value | $ 2.45B | $ 1.90B | $ 1.07B | $ 979.54M | $ 535.28M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.08 | 0.09 | 0.16 | 0.17 | 0.18 |
| Debt-to-Equity Ratio | 0.11 | 0.11 | 0.22 | 0.24 | 0.26 |
| Debt-to-Capital Ratio | 0.10 | 0.10 | 0.18 | 0.19 | 0.20 |
| Long-Term Debt-to-Capital Ratio | 0.09 | 0.10 | 0.11 | 0.19 | 0.20 |
| Financial Leverage Ratio | 1.25 | 1.24 | 1.38 | 1.38 | 1.41 |
| Debt Service Coverage Ratio | 22.43 | 14.99 | 0.56 | 16.11 | 3.83 |
| Interest Coverage Ratio | 48.95 | 38.23 | 10.72 | 10.08 | -5.37 |
| Debt to Market Cap | 0.05 | 0.05 | 0.06 | 0.06 | 0.07 |
| Interest Debt Per Share | 3.41 | 3.48 | 5.93 | 5.99 | 6.04 |
| Net Debt to EBITDA | -1.17 | -0.45 | 1.11 | 1.39 | 10.59 |
| Profitability Margins | |||||
| Gross Profit Margin | 77.13% | 79.67% | 78.01% | 76.00% | 74.52% |
| EBIT Margin | 15.32% | 19.42% | 8.37% | 7.80% | -3.28% |
| EBITDA Margin | 17.79% | 22.79% | 12.68% | 12.66% | 2.57% |
| Operating Profit Margin | 16.56% | 16.97% | 7.68% | 7.68% | -4.46% |
| Pretax Profit Margin | 14.98% | 18.98% | 7.79% | 7.14% | -4.08% |
| Net Profit Margin | 10.83% | 14.96% | 6.93% | 6.75% | -3.47% |
| Continuous Operations Profit Margin | 10.83% | 14.96% | 6.93% | 6.75% | -3.47% |
| Net Income Per EBT | 72.31% | 78.79% | 88.91% | 94.64% | 85.04% |
| EBT Per EBIT | 90.44% | 111.89% | 101.50% | 92.92% | 91.51% |
| Return on Assets (ROA) | 4.59% | 6.11% | 2.45% | 2.22% | -1.07% |
| Return on Equity (ROE) | 5.73% | 7.54% | 3.39% | 3.08% | -1.50% |
| Return on Capital Employed (ROCE) | 7.81% | 7.59% | 3.28% | 2.78% | -1.51% |
| Return on Invested Capital (ROIC) | 5.64% | 5.96% | 2.68% | 2.63% | -1.28% |
| Return on Tangible Assets | 4.86% | 6.53% | 2.64% | 2.42% | -1.18% |
| Earnings Yield | 3.06% | 3.42% | 0.93% | 0.74% | -0.40% |
| Efficiency Ratios | |||||
| Receivables Turnover | 3.55 | 4.32 | 3.82 | 4.54 | 4.94 |
| Payables Turnover | 2.36 | 2.46 | 1.69 | 2.18 | 2.36 |
| Inventory Turnover | 0.57 | 0.47 | 0.48 | 0.56 | 0.61 |
| Fixed Asset Turnover | 3.38 | 2.74 | 2.27 | 1.95 | 1.78 |
| Asset Turnover | 0.42 | 0.41 | 0.35 | 0.33 | 0.31 |
| Working Capital Turnover Ratio | 1.11 | 1.30 | 1.23 | 1.08 | 1.03 |
| Cash Conversion Cycle | 591.40 | 711.80 | 638.71 | 561.30 | 521.42 |
| Days of Sales Outstanding | 102.91 | 84.48 | 95.61 | 80.33 | 73.82 |
| Days of Inventory Outstanding | 643.42 | 775.41 | 759.54 | 648.76 | 602.50 |
| Days of Payables Outstanding | 154.93 | 148.08 | 216.44 | 167.79 | 154.90 |
| Operating Cycle | 746.33 | 859.89 | 855.15 | 729.09 | 676.32 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 4.32 | 3.01 | 0.85 | 0.95 | 1.67 |
| Free Cash Flow Per Share | 3.78 | 2.50 | 0.33 | 0.30 | 1.01 |
| Dividend Paid and CapEx Coverage Ratio | 8.04 | 5.88 | 1.65 | 1.45 | 2.55 |
| Capital Expenditure Coverage Ratio | 8.04 | 5.88 | 1.65 | 1.45 | 2.55 |
| Operating Cash Flow Coverage Ratio | 1.29 | 0.88 | 0.15 | 0.16 | 0.28 |
| Operating Cash Flow to Sales Ratio | 0.26 | 0.20 | 0.07 | 0.08 | 0.16 |
| Free Cash Flow Yield | 6.36% | 3.81% | 0.35% | 0.29% | 1.15% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 32.65 | 29.26 | 108.03 | 135.44 | -252.11 |
| Price-to-Sales (P/S) Ratio | 3.54 | 4.38 | 7.49 | 9.15 | 8.75 |
| Price-to-Book (P/B) Ratio | 1.87 | 2.21 | 3.66 | 4.17 | 3.79 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 15.72 | 26.27 | 289.46 | 348.96 | 87.18 |
| Price-to-Operating Cash Flow Ratio | 13.77 | 21.80 | 113.72 | 109.00 | 53.05 |
| Price-to-Earnings Growth (PEG) Ratio | -1.71 | 0.19 | 6.32 | -0.43 | 2.35 |
| Enterprise Value Multiple | 18.73 | 18.75 | 60.15 | 73.64 | 351.17 |
| Enterprise Value | 10.73B | 12.20B | 18.45B | 19.54B | 16.66B |
| EV to EBITDA | 18.73 | 18.75 | 60.15 | 73.64 | 351.17 |
| EV to Sales | 3.33 | 4.27 | 7.63 | 9.32 | 9.02 |
| EV to Free Cash Flow | 14.80 | 25.66 | 294.90 | 355.68 | 89.89 |
| EV to Operating Cash Flow | 12.96 | 21.29 | 115.86 | 111.10 | 54.70 |
| Tangible Book Value Per Share | 29.60 | 27.40 | 23.75 | 21.96 | 20.13 |
| Shareholders’ Equity Per Share | 31.74 | 29.77 | 26.36 | 24.85 | 23.33 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.28 | 0.21 | 0.11 | 0.05 | 0.15 |
| Revenue Per Share | 16.80 | 15.02 | 12.88 | 11.31 | 10.10 |
| Net Income Per Share | 1.82 | 2.25 | 0.89 | 0.76 | -0.35 |
| Tax Burden | 0.72 | 0.79 | 0.89 | 0.95 | 0.85 |
| Interest Burden | 0.98 | 0.98 | 0.93 | 0.92 | 1.24 |
| Research & Development to Revenue | 0.29 | 0.26 | 0.31 | 0.31 | 0.34 |
| SG&A to Revenue | 0.40 | 0.35 | 0.17 | 0.18 | 0.19 |
| Stock-Based Compensation to Revenue | 0.06 | 0.07 | 0.09 | 0.09 | 0.11 |
| Income Quality | 2.37 | 1.34 | 0.95 | 1.24 | -4.75 |
Currency in USD
